Доказательная база аторвастатина: международные и отечественные исследования
Сусеков А.В., Горнякова Н.Б. Доказательная база аторвастатина: международные и отечественные исследования. Consilium Medicum. 2008; 10 (11): 98–104.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholersterol in Adults.Summary of the Second Report of the National Cholesterol Education Programm (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269 (23): 3015–23.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486–97.
3. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group.Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 (11): 987–1003.
4. Fourth Joint Task Force of the European Society of cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (Constituted by reprtesentatives of nine societies and by invited experts).European guidelines on cardiovascular disease prevention in clinical precatice:executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2): S1–113.
5. Jones P, Kafonek S, Laurora I, Hunninghake D for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES Study). Am J Cardiol 1998: 81 (5): 582–7.
6. Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70–6.
7. Schwartz GG, Ollson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACL) study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711–8.
8. Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48 (12): 2482–5.
9. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. (ASCOT –LLA): a multicentre controlled lipid -lowering trial. Lancet 2003; 361: 1149–58.
10. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291 (9): 1071–80.
11. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352 (14): 1425–35.
12. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
13. Pedersen TR, Faergeman O, Kastelein JJP et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437–45.
14. Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357 (9256): 574–81.
15. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor.Arteriosclerosis Thromb Vascular Biology 1995; 15: 678–82.
16. Andrews TC et al. Am J Med 2001; 111: 185–91.
17. Insull W et al. Am J Cardiol. 2001; 87: 554–9.
18. Pearson TL. Arch Intern Med 2000; 160: 459–67.
19. Grundy SM, Cleeman JI et al. Implication of Recent Clinical Trials for the National Cholesterol Education Programm Adult Treatment Panel III Guidelines Circulation 2004; 110: 227–39.
20. Сусеков А.В., Зубарева М.Ю.,Трипотень М.И. и др. Кардиология. 2006; 9: 4–10.
21. Newman CB, Palmer G, Silbershatz H. et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Card 2003; 92: 670–6.
22. Rall FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.Atherosclerosis. 2000; 150 (2): 421–8.
23. Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г. и др. от имени рабочей группы исследования АТЛАНТИКА. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология. 2008, 11: 4–13.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486–97.
3. Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group.Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24 (11): 987–1003.
4. Fourth Joint Task Force of the European Society of cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (Constituted by reprtesentatives of nine societies and by invited experts).European guidelines on cardiovascular disease prevention in clinical precatice:executive summary. Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2): S1–113.
5. Jones P, Kafonek S, Laurora I, Hunninghake D for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES Study). Am J Cardiol 1998: 81 (5): 582–7.
6. Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70–6.
7. Schwartz GG, Ollson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACL) study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711–8.
8. Colhoun HM, Betteridge DJ, Durrington PN et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48 (12): 2482–5.
9. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. (ASCOT –LLA): a multicentre controlled lipid -lowering trial. Lancet 2003; 361: 1149–58.
10. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291 (9): 1071–80.
11. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352 (14): 1425–35.
12. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
13. Pedersen TR, Faergeman O, Kastelein JJP et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437–45.
14. Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357 (9256): 574–81.
15. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor.Arteriosclerosis Thromb Vascular Biology 1995; 15: 678–82.
16. Andrews TC et al. Am J Med 2001; 111: 185–91.
17. Insull W et al. Am J Cardiol. 2001; 87: 554–9.
18. Pearson TL. Arch Intern Med 2000; 160: 459–67.
19. Grundy SM, Cleeman JI et al. Implication of Recent Clinical Trials for the National Cholesterol Education Programm Adult Treatment Panel III Guidelines Circulation 2004; 110: 227–39.
20. Сусеков А.В., Зубарева М.Ю.,Трипотень М.И. и др. Кардиология. 2006; 9: 4–10.
21. Newman CB, Palmer G, Silbershatz H. et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Card 2003; 92: 670–6.
22. Rall FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.Atherosclerosis. 2000; 150 (2): 421–8.
23. Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г. и др. от имени рабочей группы исследования АТЛАНТИКА. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология. 2008, 11: 4–13.
Авторы
А.В.Сусеков, Н.Б.Горнякова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.